Trial Profile
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-629; MK-3475-629/KEYNOTE-629
- Sponsors Merck Sharp & Dohme Corp.
- 09 Nov 2023 Results from second interim analysis published in the Dermatology and Therapy
- 27 Sep 2023 Status changed from active, no longer recruiting to completed.
- 03 Jun 2023 Results presented in a Merck & Co Media Release.